BRAFV600E and BRAF-inactivating mutations in NSCLC
Mené sur 36 patients atteints d'un cancer métastatique du poumon non à petites cellules présentant la mutation BRAF V600E, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité d'un traitement de première ligne combinant dabrafénib et tramétinib
BRAF mutations, both V600E (ie, Val600Glu) and non V600E, are found in 6–8% of non-small-cell lung cancer (NSCLC)1 and cause downstream activation of the MAPK signalling pathway. Selective BRAF inhibitors, such as dabrafenib, led to 33% (95% CI 23–45) of patients achieving a response, and a median progression-free survival of 5·5 months (3·4–7·3) in patients with previously treated BRAFV600E-mutant NSCLC.2 The inhibition of RAF, together with its downstream kinase, MEK, has shown responses in BRAFV600E-mutant melanomas and NSCLCs.
The Lancet Oncology , commentaire, 2016